Pipelines - ETES

Alfa Cytology's endogenous T-cell engagement system (ETES™) pipeline highlights our structured and strategic approach to developing next-generation cancer immunotherapies. Leveraging our proprietary ETES™, our pipeline features several promising preclinical projects targeting a range of challenging cancer indications, demonstrating our dedication to pioneering safe and effective therapies.

Projects	Modalities	Disease	Discovery	Preclinical	IND	Phase I	Phase II	Phase III
ETES-01	ETES Modules	Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC)
ETES-02	ETES Modules	Triple-negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC)
ETES-03	ETES Modules	Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
ETES-04	ETES Modules	Pancreatic Cancer, Ovarian Cancer, Glioblastoma

Join Alfa Cytology's mission to revolutionize cancer immunotherapy. We seek collaborative partnerships to accelerate innovative therapies from preclinical studies toward clinical translation.

Interested in collaboration or learning more about our pipeline? Contact us today to explore strategic partnerships and advance your research objectives.

Let's Discuss About Your Project

* Your Name

* E-mail Address

Phone Number

* Services Interested

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and therapeutic services for individuals.